Education
About Us
Working with TipRanks
Follow Us
Renovaro Biosciences (RENB)
NASDAQ:RENB
RENB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.13 - $2.10
Previous CloseN/A
Volume455.11K
Average Volume (3M)2.55M
Market Cap
$30.15M
Enterprise ValueN/A
Total Cash (Recent Filing)$1.63M
Total Debt (Recent Filing)$7.03M
Price to Earnings (P/E)―
Beta2.15
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding231,780,440
10 Day Avg. Volume5,848,159
30 Day Avg. Volume2,547,857
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)1.14
Price to Sales (P/S)0.00
P/FCF Ratio-13.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Renovaro Biosciences News
RENB FAQ
What was Renovaro Biosciences’s price range in the past 12 months?
Renovaro Biosciences lowest stock price was $0.13 and its highest was $2.10 in the past 12 months.
What is Renovaro Biosciences’s market cap?
Renovaro Biosciences’s market cap is $30.15M.
When is Renovaro Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Renovaro Biosciences’s earnings last quarter?
Currently, no data Available
Is Renovaro Biosciences overvalued?
According to Wall Street analysts Renovaro Biosciences’s price is currently Overvalued.
Does Renovaro Biosciences pay dividends?
Renovaro Biosciences does not currently pay dividends.
What is Renovaro Biosciences’s EPS estimate?
Renovaro Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renovaro Biosciences have?
Renovaro Biosciences has 231,780,440 shares outstanding.
What happened to Renovaro Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Renovaro Biosciences?
Currently, no hedge funds are holding shares in RENB
Renovaro Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.86%
12-Months-Change
Fundamentals
Return on Equity
-67.13%
Trailing 12-Months
Asset Growth
-33.89%
Trailing 12-Months
Company Description
Renovaro Biosciences
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Technical Analysis
Ownership Overview
8.07% Insiders
3.53% Mutual Funds
0.09% Other Institutional Investors
86.48% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---